Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.

This case report presents a 46-year-old woman with type 2 diabetes mellitus (T2DM) who sought to discontinue glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) therapy while maintaining her weight and metabolic health. Her desire to reduce medication dependency, combined with her apprehension about potential metabolic regression following discontinuation of the drug, highlights a challenge often faced by patients managing chronic conditions, and the value of naturopathic adjunctive therapies to support these individuals in their wellness goals. This report details a comprehensive intervention strategy combining probiotics, nutrient supplementation, and lifestyle modifications to address her concerns. Over an 8-week period post-GLP-1 RAs therapy discontinuation, she maintained weight loss, improved glycemic control and lipid profile, demonstrated improvements in micronutrient levels, and experienced improvements in her quality of life. This case contributes to the growing body of evidence suggesting that targeted naturopathic interventions can play a supportive role in managing T2DM and mitigating the reliance on pharmacotherapy without compromising health outcomes.

Authors

Publication Details

Journal
PubMed
Published
2025-02-01
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.

Lilly Linder
PubMed
Pharmacology and Obesity Treatment
article

Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.

Lilly Linder
article en

Abstract

This case report presents a 46-year-old woman with type 2 diabetes mellitus (T2DM) who sought to discontinue glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) therapy while maintaining her weight and metabolic health. Her desire to reduce medication dependency, combined with her apprehension about potential metabolic regression following discontinuation of the drug, highlights a challenge often faced by patients managing chronic conditions, and the value of naturopathic adjunctive therapies to support these individuals in their wellness goals. This report details a comprehensive intervention strategy combining probiotics, nutrient supplementation, and lifestyle modifications to address her concerns. Over an 8-week period post-GLP-1 RAs therapy discontinuation, she maintained weight loss, improved glycemic control and lipid profile, demonstrated improvements in micronutrient levels, and experienced improvements in her quality of life. This case contributes to the growing body of evidence suggesting that targeted naturopathic interventions can play a supportive role in managing T2DM and mitigating the reliance on pharmacotherapy without compromising health outcomes.

PubMedVol. 24(1)
Openalex Percentile: Top 97%
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report. — Lilly Linder · PubMed (2025) | TGRS Research Map | TGRS